This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
In Reply. —
We appreciate Dr Benton's incisive letter, and we agree fully with his ultimate conclusion: Sandoz would like to rid itself of this controversy. But even more important, we would like to see clozapine reach more of the severely ill schizophrenics who have had no significant relief from crippling symptoms when treated with old-fashioned neuroleptic drugs. In recent months, we have done much to achieve both of those goals, while ensuring that the breakthrough of clozapine therapy remains available to the patients who so desperately need it, despite potentially fatal adverse reactions.In December, we announced our intention to separate the monitoring of clozapine from sales of the drug itself. On January 14, we announced a new wholesale pricing policy for clozapine tablets to make certain that physicians, providers, funders, and patients understand that separation. We are engaged in discussions with providers and funders on criteria to determine
Honigfeld G. Sandoz and the Monitoring of Patients Receiving Clozapine-Reply. JAMA. 1991;265(12):1529. doi:10.1001/jama.1991.03460120042030
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: